Cargando…

CD4(+) cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time

BACKGROUND: CD4(+) cell count is a key measure of HIV disease progression, and the basis of successive international guidelines for treatment initiation. CD4(+) cell dynamics are used in mathematical and econometric models for evaluating public health need and interventions. Here, we estimate rates...

Descripción completa

Detalles Bibliográficos
Autores principales: Cori, Anne, Pickles, Michael, van Sighem, Ard, Gras, Luuk, Bezemer, Daniela, Reiss, Peter, Fraser, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645962/
https://www.ncbi.nlm.nih.gov/pubmed/26558543
http://dx.doi.org/10.1097/QAD.0000000000000854
Descripción
Sumario:BACKGROUND: CD4(+) cell count is a key measure of HIV disease progression, and the basis of successive international guidelines for treatment initiation. CD4(+) cell dynamics are used in mathematical and econometric models for evaluating public health need and interventions. Here, we estimate rates of CD4(+) decline, stratified by relevant covariates, in a form that is clinically transparent and can be directly used in such models. METHODS: We analyse the AIDS Therapy Evaluation in the Netherlands cohort, including individuals with date of seroconversion estimated to be within 1 year and with intensive clinical follow-up prior to treatment initiation. Owing to the fact that CD4(+) cell counts are intrinsically noisy, we separate the analysis into long-term trends of smoothed CD4(+) cell counts and an observation model relating actual CD4(+) measurements to the underlying smoothed counts. We use a monotonic spline smoothing model to describe the decline of smoothed CD4(+) cell counts through categories CD4(+) above 500, 350–500, 200–350 and 200 cells/μl or less. We estimate the proportion of individuals starting in each category after seroconversion and the average time spent in each category. We examine individual-level cofactors which influence these parameters. RESULTS: Among untreated individuals, the time spent in each compartment was 3.32, 2.70, 5.50 and 5.06 years. Only 76% started in the CD4(+) cell count above 500 cells/μl compartment after seroconversion. Set-point viral load (SPVL) was an important factor: individuals with at least 5 log(10) copies/ml took 5.37 years to reach CD4(+) cell count less than 200 cells/μl compared with 15.76 years for SPVL less than 4 log(10) copies/ml. CONCLUSION: Many individuals already have CD4(+) cell count below 500 cells/μl after seroconversion. SPVL strongly influences the rate of CD4(+) decline. Treatment guidelines should consider measuring SPVL, whereas mathematical models should incorporate SPVL stratification.